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INTRODUCTION 
Osteoarthritis (OA) is the most prevalent form 
of arthritis worldwide and is a leading cause 
of chronic pain and disability, resulting in a 
huge medical and socioeconomic burden.1,2 
The condition most commonly affects ageing 
populations worldwide, compounded by the 
rise in common risk factors, including obesity, 
previous injury, and joint overuse.3 Current 
Abstract
Osteoarthritis (OA) is the most prevalent form of arthritis worldwide and affects the whole 
joint. Changes in cartilage integrity, subchondral bone, and synovitis are recognised during OA 
progression. Although advances have been made in our understanding of OA pathophysiology, 
there are no current treatments that halt the progression of the disease. Treatments are largely 
based on physical therapies to improve joint function, anti-inflammatory agents to manage pain, and 
joint replacement surgery for late-stage disease in large weight-bearing joints. There is, therefore, 
an urgent need to better understand OA pathophysiology, which could help in the development of 
new treatments. The aim of this article is to review the evidence for structural correlates of pain 
and reduced joint function in OA; the data available for different joint compartments, including 
cartilage, bone, and the synovium, and their association with symptoms of OA are summarised and 
the use of imaging tools in assisting the understanding of OA pathophysiology is discussed. In recent 
years, more advanced imaging techniques, including MRI, have led to an improved understanding of 
changes at the bone–cartilage interface in OA, with a recognition that loss of integrity at this 
junction and development of bone marrow lesions (BML) in the subchondral bone are associated 
with OA pain in large epidemiological studies. One of the main challenges in OA BML research 
has been identifying the structural characteristics and patterns of gene and protein expression. 
Gene analyses of BML have demonstrated that they are highly metabolically active structures, 
providing evidence of angiogenesis, new bone and cartilage formation, and expression of 
neurotrophic factors. Findings from genomic and proteomic studies of BML, which are discussed in 
this review, have contributed to the identification of new molecular targets and an increase in our 
understanding of OA pathophysiology.
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concepts consider OA to be a spectrum of 
overlapping disorders, often with a multifactorial 
aetiopathogenesis and common biological, 
morphologic, and clinical endpoints, resulting 
in the structural and functional failure of the 
synovial joint.4,5 OA can occur in all synovial 
joints but is most commonly seen in large 
weight-bearing joints, such as the hand, 
hip, knee, and spine, which have the greatest 
impact on disability.6
OA was previously considered to be a 
disease affecting articular cartilage; however, 
current theories suggest OA has a complex 
pathogenesis involving all structures of the joint, 
including the subchondral bone, ligaments, 
capsule, and synovial membrane.5,6 Visualisation 
of changes in the bone and other structures in 
the OA joint has been aided by the advent of 
MRI-based assessments.7 More recent studies 
have demonstrated that bone marrow lesions 
(BML) are an integral component of structural 
damage in OA and are likely to be a cause of 
pain.8 Large cohort studies, such as MOST,9 
have supported observations that larger BML 
are associated with symptomatic OA and that 
synovitis, in particular detected by contrast-
enhanced MRI, also contributes to OA symptoms 
of pain and impaired function. Other studies 
have also indicated increasing MRI-identified 
cartilage loss associated with OA progression; for 
example, in the large dataset of the OAI study.10
Joint degeneration often results in patients 
presenting with clinical symptoms, such as 
chronic pain, joint instability, and stiffness, 
leading these patients to seek care. As the 
condition worsens, structural changes become 
more apparent, including radiographic changes, 
such as joint space narrowing, osteophytosis, 
and subchondral sclerosis, often visible during 
disease progression. However, there is evidence 
to suggest a poor association between 
radiographic joint changes and symptoms, 
with pain sensitisation reported by many 
subjects in a study of knee OA.11 Recent work 
has also shown OA structural changes present 
in asymptomatic groups.12 There are data to 
suggest that certain stratified OA subsets can 
worsen over time, in comparison to other types 
of OA, for which symptoms can stabilise.12 
There are currently few therapies that reverse 
OA progression or arrest its development. 
Recent studies have suggested that invasive 
ankle joint distraction may encourage cartilage 
regrowth and functional improvement.13 
Furthermore, recently, knee joint distraction 
has shown evidence of tissue repair14 and knee 
osteotomy surgery has shown promise of 
cartilage regrowth and preservation of function.15 
Nonsurgical management options include 
implementing nonpharmacological treatments 
to improve joint function and reduce stiffness, 
e.g., weight loss, low-impact exercise, and 
orthotics; and pharmacological management to 
relieve pain, e.g., analgesics, nonsteroidal anti-
inflammatory drugs (NSAID), and intra-articular 
injections. In the late stages of OA, if severe 
pain persists and patients fail to respond to 
other recommended treatments, then surgery, 
e.g., joint replacement, is considered a recourse 
to improve quality of life, reduce pain, and 
improve joint function.16 The high unmet need 
to develop novel therapeutics for OA has led 
to the investigation of BML as a therapeutic 
target for OA, with recent studies showing 
improvement in knee OA pain, function, and BML 
size after zoledronate treatment.17 Inflammatory 
changes in the OA joint, e.g., synovitis, have also 
been the focus of treatment in a recent trial 
of hydroxychloroquine in hand OA;18 however, 
hydroxychloroquine was not found to be 
effective at improving pain or function in this 
type of OA. 
IMAGING AND HISTOLOGICAL 
CHARACTERISATION OF  
BONE MARROW LESIONS
In recent years, the advancement of MRI 
techniques has improved methods of visualising 
bone and cartilage in OA, particularly at the 
bone–cartilage interface. Bone marrow signal 
changes were first described on MRI by 
Wilson et al.,19 who used the term ‘bone marrow 
oedema’ to describe MRI findings in painful 
joints. BML are observed frequently in people 
with OA and are often described as diffuse 
areas of high-intensity signal on T2-weighted, 
fat-saturated MRI or in short tau inversion 
recovery sequences.20 A large number of studies 
have delineated MRI BML changes in human 
subjects, particularly with large-joint OA.21-28 
The results of a study of individuals with 
severe hip OA undergoing joint replacement 
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established that the sum of BML measured 
via MRI corresponded to joint pain severity 
and the number of microfractures identified 
histologically.29 Kornaat et al.30 followed-up 
182 OA subjects after 2 years and established 
that the total size of BML differed in 66% of the 
subjects, concluding that BML are involved in 
a dynamic process and, unlike cartilage loss, 
are not a static outcome. In addition, several 
longitudinal investigations have demonstrated 
that areas of BML are associated with subchondral 
cysts and could in fact be early precystic lesions.31 
BML have also been strongly associated with 
cartilage degeneration, predominantly within 
areas overlying the lesion.5 
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Figure 1: Imaging and histological analysis of a bone marrow lesion and the surrounding region. 
A) Coronal and axial plane of a MRI scan visualising BML and an associated cyst. B) Macroscopic appearance of a 
BML identified by MRI at the time of tissue harvest during joint replacement surgery. C) Histology of a MRI-identified 
BML demonstrating typical pathological changes, including new blood vessels, cysts, cellular infiltrate, cartilage 
within the bone compartment, myxoid/fibrous tissue, and trabecular thickening.
BML: bone marrow lesion.
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With regard to histological analyses, studies 
have so far focussed on acquiring data from 
patients undergoing joint replacement surgery 
of the knee and hip. Zanetti et al.32 determined 
histologically that BML contain normal fatty 
marrow, with marrow necrosis, necrotic or 
remodelled trabeculae, oedema, and bone 
marrow bleeding. The same group matched 
MRI changes to BML abnormalities in a study of 
participants undergoing total knee replacement 
and found regions of normal tissue alongside 
bone marrow fibrosis, oedema, and bleeding.32 
In a study of hip and knee OA, Hunter et al.33 
reported increased bone volume fraction but 
decreased tissue mineral density within the BML 
using light microscopy. Samples from the lesion 
area showed increased trabecular thickness, 
with granulation, oedema, necrosis, fibrinoid 
deposition, and hyperplasia of the blood vessel 
walls. Taljanovic et al.29 reported one of the 
largest histological studies of hip OA BML to date, 
in which regions of fibrosis and microfracture 
formation at different stages of healing were 
observed. Leydet-Quilici et al.34 also described 
oedema, necrosis, and fibrosis within BML 
biopsies. Using MRI, Roemer et al. 35 previously 
demonstrated that progression of disease and 
the development of BML correlated with an 
increased risk of cartilage loss within the same 
subregion and that regions without BML were 
associated with a decreased risk of cartilage 
loss. Carrino et al.31 also reported that 87% of 
subchondral cysts were associated with BML 
abnormalities on MRI. 
Several pathologies are seen histologically 
within BML, including bone remodelling, 
oedema, fibrosis, osteonecrosis, and trabecular 
abnormalities.32,36 Some theories propose that 
subchondral bone ischaemia may be an initiator 
for BML by impairing nutrient and oxygen 
exchange with articular cartilage, reducing 
cartilage integrity and increasing the risk of OA 
development.37-40 Others have proposed that 
bony micro contusions resulting in necrosis 
may lead to BML. Kijowski et al.41 suggested 
that increased intra-articular pressure leads to 
the permeation of synovial fluid and cellular 
infiltrate through defects in the articular cartilage 
into the subchondral bone, resulting in the 
proliferation of myxomatous tissue within the 
bone marrow. 
PAIN AND BONE MARROW LESIONS
Recent work has shown that pain in OA arises 
from several structures within the arthritic 
joint, including the synovium (from which 
prostaglandins, leukotrienes, and inflammatory 
mediators are released), joint effusions, joint 
capsule involvement, and tendon and muscle 
weakness, which all contribute to reduced 
function.42 Synovitis is often observed by MRI 
in OA and strongly correlates with pain.35 
Cartilage degradation is one of the hallmarks of 
OA disease43 and exposes the structures from 
which pain is most likely arising, since cartilage 
is an avascular, aneural structure composed 
largely of extracellular matrix (ECM) embedded 
sparsely with chondrocytes. There has been 
growing evidence of BML correlating with 
recurrent pain and pain severity in several 
studies, particularly in large-joint OA.44-46 
A significant correlation was seen between 
the presence of larger BML in painful 
knees as opposed to non-painful knees.30,44-46 
A study evaluating BML changes over time in 
patients with painful knee OA found that, within 
3 months, BML scores decreased in 37 patients 
and increased in 71 patients.47 Epidemiological 
studies have shown a strong correlation 
between BML observed by MRI and OA-related 
knee pain in several large cohorts,44,46 with an 
odds ratio of 3.2 for the association of BML with 
pain. These data demonstrate the multifactorial 
nature of OA and how pain mechanisms are 
supported by the biopsychosocial model of pain.
GENE AND PROTEIN EXPRESSION  
IN BONE MARROW LESIONS
Although a large body of data now exists 
describing how BML are implicated in OA 
disease onset and progression, with descriptions 
of their histology and histomorphometry, 
very few studies evaluating the genetic and 
protein expression of BML have been conducted. 
This study group recently conducted a 
transcriptomic study of BML in OA.48 The novel 
findings demonstrated that BML have features of 
angiogenesis, fibrosis, new cartilage formation, 
and increased bone turnover, with disruption 
of the physiological osteochondral interface. 
In addition, a whole transcriptomic analysis of 
BML regions was used, finding upregulated 
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expression of genes involved in neurogenesis, 
pain sensitisation, chemokine and cytokine 
signalling, as well as cartilage remodelling 
pathways.48 A multimodal approach with MRI 
to locate knee OA BML was also performed, 
followed by detailed histological analyses 
and whole transcriptomic techniques for a 
multivariate interrogation of the changes 
seen within BML. Detailed MRI matching with 
histological techniques allowed improved 
visualisation of BML, with direct observation 
of BML-associated cystic structures using MRI 
and transcriptomic expression analyses. Higher 
Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) pain scores 
with greater MRI Osteoarthritis Knee Score 
(MOAKS)-measured tricompartmental damage 
in advanced versus mild OA were found, 
as shown by previous studies.46 
Cystic BML areas have been shown to be 
surrounded by regions of fibrosis, infiltration by 
inflammatory cells, and vascular proliferation. 
Previous hypotheses that BML could be 
precystic but that not all BML become cystic 
are also supported by the histological findings 
in this study and from other groups.31 It has been 
observed that cystic structures found within 
the BML areas using MRI were cysts but were 
also adjacent to areas of fibrocartilage, vascular 
proliferation, chondrogenesis, and amorphous 
tissue deposition (Figure 1). The authors also 
observed new cartilage forming deep within 
the subchondral bone compartment (Figure 1); 
this new cartilage tissue within the BML could 
be arising from mesenchymal stem cells (MSC) 
in the marrow, which has been seen by other 
groups.49 Campbell et al.50 reported altered 
numbers and phenotypes of MSC in cultures 
isolated from hip OA BML, showing that 
BML-derived MSC undergo osteochondral 
angiogenesis and have lower proliferation and 
mineralisation capacities in vitro.
Microarray studies have shown that the highest 
upregulated gene from OA BML tissue was 
STMN2, encoding a phosphoprotein involved in 
regulating microtubule function, responsiveness 
to nerve growth factor, neuronal growth, and 
osteogenesis.48 Upregulation of STMN2 within 
BML may be involved in developing new 
neuronal structures and expansion of the BML 
in OA, thereby causing pain.51 However, STMN2 
protein expression was higher in physiological 
bone than BML bone, which could reflect 
increased STMN2 turnover in OA BML or loss to 
the circulation due to increased tissue damage. 
The authors’ microarray study also identified 
neuronal markers, including THBS4, involved in 
the inflammatory response to central nervous 
system injury, presynaptic hypersensitivity, and 
neuropathic pain states.52 In animal models of 
pain sensitisation, THBS4 is increased locally in 
dorsal root ganglion neurons and contributes 
to pain behaviour, which can be inhibited by 
the calcium channel modulator gabapentin.53 
Genes implicated in neuronal morphogenesis 
have also been identified in BML, including 
ATP6V0D2, PSIP1, NYAP2, FERM, and FRMPD4, 
encoding proteins implicated in central nervous 
system development and pain states.54,55 ECM 
genes have also been associated with BML, 
including MMP13 and collagen genes, COL16A1, 
and those encoding fibronectins and growth 
factors that are known to be bound within 
the ECM.56 
BML are regions of high metabolic activity 
with increased cell turnover, bone remodelling, 
and neuronal and inflammatory gene signatures, 
and gene ontological analyses have revealed the 
involvement of canonical pathways in chemokine, 
integrin, and cytokine signalling. There is 
evidence of neurodevelopment and pain pathway 
signalling represented by the Alzheimer’s, Notch, 
catenin, and Wnt pathways, alongside vascular 
endothelial growth factor and angiogenic 
pathway expression. Studies by Hopwood57 
and Chou et al.58 analysing the gene expression 
profiles of OA bone showed expression of bone 
remodelling signalling pathways, including 
Wnt, TGF-β, and bone morphogenic protein 
(BMP), and bone remodelling molecules, 
such as periostin and leptin. Additionally, 
Kusumbe et al.59 described how the growth of 
blood vessels in bone and osteogenesis are 
coupled, proposing that Type H endothelial 
cells mediate local growth of the vasculature 
and provide specific signals for perivascular 
osteoprogenitors. The same group reported 
that endothelial Notch activity promotes 
angiogenesis and osteogenesis in bone.60 The 
authors have also demonstrated OMD expression 
in BML tissue and Ninomiya et al.61 showed that 
osteoclast activity induces OMD expression in 
bone, suggesting BML represent areas of active 
bone remodelling. 
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The expression of angiogenic and osteogenic 
genes, along with the tissue changes identified 
in BML, suggest that vascular proliferation and 
bone formation are likely to be coupled in BML 
development. Since blood vessels are formed 
within neurovascular bundles, it is likely that the 
increased neuronal pathway gene expression, 
including STMN2, THBS4, PSIP1, NYAP2, 
and genes encoding catenin, which are among 
some of the most highly expressed genes in 
BML analyses, are implicated in neural pathway 
development, nerve formation, and pain 
mediation in BML tissue.
Gene arrays of BML have also identified 
molecules within the Wnt signalling pathway, 
including catenin, and other studies have 
demonstrated a critical role of Wnt signalling in 
the production and persistence of neuropathic 
pain after nerve injury and bone cancer.62 
Studies using rodent models have suggested 
that in nerve injury and bone cancer pain 
models,  Wnt signalling is activated, which may 
contribute to pain by regulating proinflammatory 
cytokines IL-18 and TNF-α, respectively, as well 
as NR2B and subsequent Ca2+-dependent signals 
in the dorsal horn. This analysis also showed a 
high representation of inflammatory chemokines 
and cytokine signalling, while other groups have 
also identified chemokines involved in OA pain; 
for example, CCR2 was recently reported to 
mediate pain in a murine model of OA.63 
Microarray data suggest that chemokine pathway 
molecules could be pain sensitisers in BML.48 
Walsh et al.64 highlighted that OA neurovascular 
changes at the osteochondral junction, 
including vessels and both sensory and 
sympathetic nerves breaching the tidemark, 
could be a source of joint pain. The genes 
identified in BML transcriptomic analyses 
support the hypothesis of neurovascular gene 
upregulation in BML tissue.
One of the most highly expressed genes in BML 
tissue is MMP13, traditionally thought to encode 
an enzyme expressed in cartilage that is 
involved in regulating ECM turnover and 
cartilage destruction in OA.65 Increased bone 
matrix microdamage and altered vasculature in 
the subchondral bone of BML have also been 
demonstrated in a recent histological study of 
73 subjects undergoing knee joint replacement 
surgery.66 Supporting the importance of matrix 
turnover in OA, data have shown that Type II 
collagen degradation products are increased 
in the urine of subjects with advanced OA who 
had MRI-identified BML.48 The de novo cartilage 
formation observed within BML, coupled with 
the increased transcriptomic expression of 
MMP13 observed using microarray and the 
detection of MMP13 cleavage products, could 
suggest recapitulation of the embryonic bone 
development phenotype within OA BML regions. 
Although much has been learned over the last 
few years with respect to gene expression and 
protein turnover at the osteochondral interface 
in OA, further validation of the molecules 
identified and their relative importance in distinct 
stages of OA pathophysiology is required. 
Validation of genes and proteins involved in 
matrix turnover, angiogenesis, and neurogenesis 
will not only assist in OA disease stratification 
but will also identify therapeutic targets.67 
It is conceivable that information on pertinent 
molecular markers in OA, coupled with MRI data, 
may assist in improved patient stratification 
that could help in developing more targeted 
treatments for people with OA.
SUMMARY
Recent work, supported by MRI studies and 
tissue analyses, has demonstrated that OA is 
a disease of the whole joint. Symptoms of pain 
and impaired function are influenced by joint 
synovitis, joint effusion, tendon and ligament 
involvement, and the presence of BML, which 
are most easily detected by MRI. BML in OA 
represent regions of high metabolic activity, 
with expression of genes involved in neuronal 
development, pain, ECM turnover, cartilage and 
bone formation, and angiogenesis. Recent work 
focussing on the bone–cartilage interface in OA 
and the deeper underlying bone has revealed 
that BML development is an important step in 
OA pathogenesis. The new findings from gene 
array and protein studies of BML suggest the 
possibility of developing new diagnostic tools; 
for example, identifying angiogenesis and 
bone turnover markers based on ECM turnover. 
However, further evaluation is required of the 
genes associated with specific markers of 
BML region, size, and severity. It is also possible 
that the enlargement of BML is associated with 
specific markers identified from gene array 
studies, which requires further work to evaluate 
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BML at different stages of development and 
formation. It is conceivable that in the future, 
combined testing of molecular markers identified 
from the synovia, cartilage, and BML with MRI 
of the target joint may be used to assess the 
degree and severity of damage of an OA joint. 
The findings from BML functional tissue studies 
also raise the possibility of developing future 
therapies targeting BML formation and turnover 
for OA, which is the most common arthritic 
disease worldwide.  
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